Parsons-Doherty Melissa, Poirier Valerie J, Monteith Gabrielle
Animal Cancer Centre, Ontario Veterinary College Health Sciences Centre (Parsons-Doherty, Poirier), and Department of Clinical Studies, Ontario Veterinary College, (Monteith), University of Guelph, Guelph, Ontario N1G 2W1.
Can Vet J. 2014 Feb;55(2):175-80.
In this retrospective study, a chemotherapy protocol using dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) was evaluated for efficacy and adverse event profile as a first line rescue protocol in 86 client-owned dogs previously treated with a CHOP-based protocol. Forty-three dogs (43%) achieved remission (16% complete remission, 27% partial remission), and 57% were non-responders. The median overall progression-free survival (PFS) was 24 days. Adverse events included thrombocytopenia in 41% of dogs, neutropenia in 17% of dogs, and gastrointestinal toxicity in 13% of dogs. Overall, 16% (13/79) dogs experienced grade III to IV thrombocytopenia, 8% (6/74) dogs grade III to IV neutropenia and 1% (1/79) dogs grade III to IV gastrointestinal toxicity. The efficacy of the DMAC protocol is similar to that of other rescue protocols in dogs with relapsed lymphoma but is associated with shorter PFS. The main toxicity is thrombocytopenia, which may limit treatment.
在这项回顾性研究中，对一种使用地塞米松、美法仑、放线菌素D和阿糖胞苷（DMAC）的化疗方案进行了疗效和不良事件分析，该方案作为一线挽救方案应用于86只曾接受基于CHOP方案治疗的家养犬。43只犬（43%）实现缓解（16%完全缓解，27%部分缓解），57%无反应。中位总无进展生存期（PFS）为24天。不良事件包括41%的犬出现血小板减少，17%的犬出现中性粒细胞减少，13%的犬出现胃肠道毒性。总体而言，16%（13/79）的犬经历III至IV级血小板减少，8%（6/74）的犬经历III至IV级中性粒细胞减少，1%（1/79）的犬经历III至IV级胃肠道毒性。DMAC方案的疗效与其他用于复发淋巴瘤犬的挽救方案相似，但PFS较短。主要毒性是血小板减少，这可能会限制治疗。
